By Abby Hardy As president of Chardan, an independent, global investment bank specializing in healthcare, disruptive technologies, and special purpose acquisition companies (SPACs), Jonas Grossman takes a worldwide view...
Arcus Biosciences (NYSE:RCUS) appointed Eric Hoefer as its chief commercial officer to oversee the company’s global commercial strategy and operations.
Zenabis Global (TSX:ZENA) generated cultivation output in May of 908 kg of dried cannabis, which represents a 35.1% outperformance relative to design capacity.
ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that the FDA provided positive feedback to the company’s pre-IND meeting regarding CRV431 for the treatment of non-alcoholic steatohepatitis (NASH).
BTIF downgraded Verastem (NASDAQ:VSTM) to “neutral” from “buy” and removed its previous price target of $8 after the company announced that president and CEO, Robert Forrester, was stepping down. The stock closed at $1...
PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported initial results from its Phase 2a trial assessing PB2452’s ability to reverse the effects of the antiplatelet drug, ticagrelor, in subjects 50-to-80 years of age.
Closely-held Lutronic Vision’s R:GEN laser has treated its first central serous chorioretinopathy (CSC) patient at Seoul National University Hospital (SNUH).